Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04973163 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | active not recruiting | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 4 | Feb 17, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407985 | A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors(GK01IIT-TZ03) | active not recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04078295 | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 125 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05359237 | Vincristine Pharmacokinetics in Infants | active not recruiting | — | 83 | Children's Oncology GroupNETWORK | 3 | Feb 6, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 500 | FBD Biologics LimitedINDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05352750 | Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Sonnet BioTherapeuticsINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05744427 | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 725 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06625619 | On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge | active not recruiting | — | 6 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06993116 | A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 15 | Guangdong Hengrui Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT05455606 | Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment | active not recruiting | N/A | 1,284 | SWOG Cancer Research NetworkNETWORK | 2 | Jan 22, 2026 | clinicaltrials |
| NCT06932952 | A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 7 | Byondis B.V.INDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07153094 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03996265 | Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors | active not recruiting | Phase 3 | 422 | University of Rochester NCORP Research BaseOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05163041 | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | active not recruiting | Phase 1 / Phase 2 | 200 | BicycleTx LimitedINDUSTRY | 2 | Jan 15, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04062552 | Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers | active not recruiting | N/A | 208 | University of Rochester NCORP Research BaseOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05156866 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | active not recruiting | Phase 1 | 163 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT06631079 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 20 | NEC Bio B.VINDUSTRY | 3 | Jan 8, 2026 | clinicaltrials |
| NCT07152353 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05868486 | Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer | active not recruiting | Early Phase 1 | 100 | City of Hope Medical CenterOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05503251 | Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases | active not recruiting | Phase 2 | 110 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06328673 | A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | active not recruiting | Phase 1 | 160 | D2M Biotherapeutics Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT05566574 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | active not recruiting | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05159700 | A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 39 | Zhuhai Yufan Biotechnologies Co., LtdINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04898543 | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 50 | ImmunityBio, Inc.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07274449 | Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors(NK) | active not recruiting | Phase 1 / Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06341114 | A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 112 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT06220318 | Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 155 | Fujian Haixi Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05715281 | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | active not recruiting | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors(MICA) | active not recruiting | Phase 1 | 440 | Cullinan Therapeutics Inc.INDUSTRY | 4 | Nov 24, 2025 | clinicaltrials |
| NCT05631899 | CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06345482 | A Study of MHB039A for Advanced Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 196 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06373406 | A Study of MHB036C for Advanced Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05119907 | Study of Sacituzumab Govitecan in Patients With Solid Tumor | active not recruiting | Phase 2 | 53 | Gilead SciencesINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06143007 | A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Broadenbio Ltd., Co.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05023993 | The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2026source: clinicaltrials